painreform.com (PRFX): Price to Earnings Adjusted for Growth Rate
The development of PainReform Ltd. (PRFX) depends on regulatory approval and the recognition of the effectiveness of new pain management systems by surgeons. A key advantage of PRF-110 is its oil-based composition, which provides pain blockage for 72 hours, ensuring strong pricing power. The peg_co ratio confirms this potential, with the value stabilizing at 0.00. Currently, the company is burning capital while awaiting the completion of tests to create market momentum.
Metric breakdowns and analytics for PainReform Ltd. (PRFX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital PainReform Ltd.|PRFX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital painreform.com|PRFX - Company Debts|Debts to Book Capitalization Ratio PainReform Limited|PRFX - Company Long-Term Debts|Company Short-Term Debts PainReform|Interim Coverage Ratio painreform.com
- earnings and market ratios statistics:
PRFX - Company Net Income|Net Profit Forecast PainReform Ltd.|PRFX - Price to Earnings Ratio|Future Price to Earnings Multiple PainReform Corp|PRFX - PEG Multiple|Company Value to EBITDA PainReform Limited|PRFX - Operating profit EBITDA|Earnings per one share for the last 12 months PainReform|PRFX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months painreform.com|PRFX - Earnings per share growth in current year|Expected earnings per share trend next year PainReform Ltd.
Fundamental company analysis:PainReform Ltd - PRFX
This indicator compares the market value of the stock with net profit dynamics to determine the investment efficiency per one percent of business growth. By analyzing the P/E ratio relative to earnings growth rates, an investor can assess the undervaluation of PainReform Ltd. (PRFX), considering the low demand elasticity for the unique drug PRF-110, which confirms the issuer's potential pricing power over the long term.
Competing companies
HLN (Haleon PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kenvue Corp KVUE|Verona Pharma Inc. (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|ligand.com - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company PLC - Growth-Adjusted Payback Ratio|ALVO (Alvotech Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liquidia Inc. LQDA|Price/Earnings to Growth Ratio Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio MannKind MNKD|AMPH (Amphastar Pharmaceuticals Inc) - Market Cap to Earnings and Growth Ratio|Pacira - PEG Multiple|SPRY - PEG Multiple|TBPH: PEG Multiple|AQST - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio scPharmaceuticals, Inc.|Growth-Adjusted P/E Ratio TECX (Tectonic)|Price/Earnings to Growth Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (sxtchina.com) - Growth-Adjusted Payback Ratio|PEG Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|bioharvest.com (BHST) - Price to Earnings Adjusted for Growth Rate|eXoZymes - PEG Multiple|Market Cap to Earnings and Growth Ratio ORMP|enterabio.com (ENTX) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate MindWalk Therapeutics (HYFT)|Price/Earnings to Growth Ratio ABVC BioPharma|CPIX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Quantum BioPharma (QNTM)|Price/Earnings to Growth Multiple FibroGen Inc FGEN|Telomir Pharma - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RANI|SNYR - Price/Earnings to Growth Ratio|RLYB: Price/Earnings to Growth Ratio|LEXX (lexariabioscience.com) - Price/Earnings to Growth Multiple|PULM: Company Value to Earnings Growth Ratio|PTHL (Pheton Holdings Limited) - PEG Multiple|Growth-Adjusted P/E Ratio APM (Aptorum)|Price/Earnings to Growth Multiple LYRA (Lyra Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income impactbiomedinc.com|Price/Earnings to Growth Ratio TNF Pharmaceuticals, Inc. TNFA|YCBD (cbdMD Inc.) - Market Cap to Earnings and Growth Ratio|CYTO - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio LIPO (Lipella Pharma)|OPTN: PEG Multiple|Market Cap to Earnings and Growth Ratio PIRS (pieris.com)|Price/Earnings to Growth Multiple PROC|Growth-Adjusted P/E Ratio PTPI (Petros Pharmaceuticals Inc)|Price/Earnings to Growth Ratio Qilian International Holding Group Limited (QLI)|SLRN: Market Cap to Earnings and Growth Ratio|PEG Multiple TFFP (TFF Pharmaceuticals)
